Behind US stock gains, gold’s climb reflects growing market uncertainty: Macquarie
Introduction & Market Context
Kusurinomadoguchi Inc (TYO:5592), a leading provider of pharmacy services and digital healthcare solutions in Japan, released its Q1 FY2026 earnings presentation on August 14, 2025. The company reported strong performance across all business segments, with consolidated net sales reaching 2.91 billion yen, an 11% increase year-over-year.
The company operates Japan’s largest domestic portal site for pharmacy services, with its EPARK Medicine Notebook app surpassing 6 million downloads. Kusurinomadoguchi maintains approximately 36.7% market share of Japan’s 63,000 pharmacies and captures about 1.7% of the country’s prescription market.
Quarterly Performance Highlights
Kusurinomadoguchi reported impressive financial results for Q1 FY2026, with growth across all key metrics. Consolidated operating profit surged 65% year-over-year to 629 million yen, representing the highest level in the company’s history. This substantial increase was attributed to higher sales across all business segments and successful cost optimization efforts.
As shown in the following consolidated financial results summary:
The company’s stock gross profit, a key performance indicator defined as sales expected to continue based on contracts such as monthly usage fees, increased by 23% year-over-year to 851 million yen. This growth was primarily driven by the Media Business and Everyone’s Medicine Box Business.
The trend in consolidated net sales shows consistent growth in both stock sales and shot sales (one-time revenues such as initial setup fees):
Similarly, the consolidated stock gross profit has shown steady improvement, reaching a new record high in Q1 FY2026:
Operating profit has also demonstrated strong growth, reaching its highest historical level in Q1 FY2026:
Detailed Financial Analysis
Kusurinomadoguchi’s consolidated statement of profit and loss reveals significant improvements across multiple financial metrics. While net income attributable to owners of the parent is progressing slower against the full-year forecast, the company expects this to align with plans following the addition of deferred tax assets related to carried-over losses in Q2, associated with the reduction of capital stock scheduled for September.
The detailed profit and loss statement shows the following performance:
The company has made progress in optimizing its cost structure, with a focus on streamlining operations in its subsidiaries. This is reflected in the trends of SG&A expenses and employee count:
Regarding the company’s balance sheet, a significant reduction in cash and current liabilities was noted, primarily due to the shift to a collection agency scheme for purchasing support services. Additionally, dividend payments and taxes were paid during Q1:
Against the full-year forecast, Kusurinomadoguchi has achieved 24% of its net sales target, 29% of its operating profit target, and 30% of its ordinary profit target in the first quarter:
Business Segment Performance
The Media Business, which includes the company’s pharmacy portal sites and mobile applications, showed strong performance with sales increasing 9% year-over-year to 11.5 billion yen. The business model combines both stock sales (recurring revenue) and shot sales (one-time fees):
The Media Business has seen consistent growth in stock sales, while shot sales have remained relatively stable:
Particularly impressive is the improvement in the Media Business’s stock gross profit, which reached 388 million yen in Q1 FY2026, a 42% increase year-over-year. The gross profit rate improved from 39% in Q1 FY2025 to 47% in Q1 FY2026, marking the highest rate historically:
The Everyone’s Medicine Box Business, which provides procurement support and inventory management solutions, also performed well with sales increasing 12% year-over-year to 8.7 billion yen and stock gross profit rising 15% to 3.8 billion yen.
The Core System Business, which offers systems for dispensing pharmacies, saw sales growth of 11% year-over-year to 8.2 billion yen, though its stock gross profit decreased by 9% to 1.4 billion yen due to upfront investments in new products.
Strategic Initiatives
Kusurinomadoguchi is implementing several strategic initiatives to enhance its service offerings and operational efficiency. A key focus is the implementation of AI-powered solutions to optimize prescription services.
The company has introduced an "AI stock function" to prevent lost opportunities in prescription net acceptance. This system addresses the problem of pharmacies not having prescribed medications in stock when patients place online reservations. By leveraging cancellation and inventory data, the AI system can proactively reach out to other patients and offer prescription services. In Q1 FY2026, this functionality was implemented in 1,089 stores.
The company is also strengthening its physical store presence with automated reception systems and ticket dispensing solutions.
Forward-Looking Statements
Kusurinomadoguchi maintains its full-year forecast for FY2026, with targets of 12.3 billion yen in net sales, 2.2 billion yen in operating profit, and 2.135 billion yen in ordinary profit. The company expects to achieve these targets through continued growth across all business segments and further cost optimization.
At the 21st Annual General Meeting of Shareholders held on June 24, 2025, the company approved a reduction of capital stock, with the effective date scheduled for September 2025. The addition of deferred tax assets related to carried-over losses associated with this capital reduction is planned for Q2, which the company expects will align net income with the full-year forecast.
As of September 8, 2025, Kusurinomadoguchi’s stock was trading at 3,815 yen, down 10 yen or 0.26% from its previous close. The stock has traded in a 52-week range of 1,201 to 4,120 yen, indicating strong overall performance despite the recent slight decline.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.